Latest From Atreca Inc.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
Peregrine, Ardelyx, Egalet and others reduced expenses and sought alternatives in the second quarter. Also, cell and gene therapy investment rises, FibroGen priced a $326m offering and Unity increased its Series B by $35m.
Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.
With basic research in immuno-oncology still very limited, there are still a lot of opportunities to develop new breakthrough therapies beyond checkpoint inhibitors, companies active in the space said during a panel at the recent Biotech Showcase.
Drug Discovery Tools
- Drug Discovery Tools
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Atreca Inc.
- Senior Management
Tito A Serafini, PhD, Pres. & CEO
Susan Berland, CFO
Paulette Dillon, SVP, Corp. Dev.
Norman M Greenberg, PhD, CSO
- Contact Info
Phone: (650) 595-2595
500 Saginaw Dr.
Redwood City, CA 94063
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.